Supplemental Figure 1: Study flow and reasons for discontinuation

960 assessed for eligibility

145 underwent randomization

72 assigned to niacin + statin and included in baseline analysis
   13 withdrew from study
   2 refused further MR scans
   3 had a nonfatal adverse event
   4 withdrew consent
   4 had flushing
   5 discontinue niacin but remain in study & analyzed according to assignment
   1 had a nonfatal adverse event
   3 had flushing
   1 had treatment failure
   59 complete 18 month assessment and included in final analysis

73 assigned to placebo + statin and included in baseline analysis
   15 withdrew from study
   1 died
   1 was lost to follow up
   4 had a nonfatal adverse event
   5 refused further MR scans
   5 withdrew consent
   2 discontinue placebo but remain in study & analyzed according to assignment
   1 had flushing
   1 had treatment failure
   58 complete 18 month assessment and included in final analysis